137 related articles for article (PubMed ID: 32750192)
1. Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England.
Mohamed Z; Scott N; Al-Kurdi D; Selvapatt N; Thursz MR; Lemoine M; Brown AS; Nayagam S
Liver Int; 2020 Dec; 40(12):2950-2960. PubMed ID: 32750192
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
3. Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England.
Mohamed Z; Al-Kurdi D; Nelson M; Shimakawa Y; Selvapatt N; Lacey J; Thursz MR; Lemoine M; Brown AS
Int J Drug Policy; 2020 Jan; 75():102608. PubMed ID: 31759307
[TBL] [Abstract][Full Text] [Related]
4. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons.
Martin NK; Hickman M; Miners A; Hutchinson SJ; Taylor A; Vickerman P
BMJ Open; 2013 Aug; 3(8):. PubMed ID: 23943776
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
12. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
[TBL] [Abstract][Full Text] [Related]
13. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.
Mafirakureva N; Stone J; Fraser H; Nzomukunda Y; Maina A; Thiong'o AW; Kizito KW; Mucara EWK; González Diaz CI; Musyoki H; Mundia B; Cherutich P; Nyakowa M; Lizcano J; Chhun N; Kurth A; Akiyama MJ; Waruiru W; Bhattacharjee P; Cleland C; Donchuk D; Luhmann N; Loarec A; Maman D; Walker J; Vickerman P
Addiction; 2022 Feb; 117(2):411-424. PubMed ID: 34184794
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
[TBL] [Abstract][Full Text] [Related]
16. Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: A model-based cost-effectiveness analysis.
Duchesne L; Dussault C; Godin A; Maheu-Giroux M; Kronfli N
Int J Drug Policy; 2021 Oct; 96():103345. PubMed ID: 34176704
[TBL] [Abstract][Full Text] [Related]
17. Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination.
Shih STF; Stone J; Martin NK; Hajarizadeh B; Cunningham EB; Kwon JA; McGrath C; Grant L; Grebely J; Dore GJ; Lloyd AR; Vickerman P; Chambers GM
Open Forum Infect Dis; 2024 Feb; 11(2):ofad637. PubMed ID: 38344130
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
[TBL] [Abstract][Full Text] [Related]
19. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
[TBL] [Abstract][Full Text] [Related]
20. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?
Manca F; Robinson E; Dillon JF; Boyd KA
Int J Drug Policy; 2020 Aug; 82():102811. PubMed ID: 32585583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]